Earnings Release • Nov 12, 2012
Earnings Release
Open in ViewerOpens in native device viewer
News Details
Corporate | 12 November 2012 07:30
MeVis Medical Solutions AG: MeVis remains on course for further profitability
MeVis Medical Solutions AG / Key word(s): Interim Report/Quarter Results
12.11.2012 / 07:30
MeVis remains on course for further profitability
Increased liquidity and a clear improvement in profitability with stable sales
Bremen, November 12, 2012 – MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, today announced its results for the first three quarters of 2012.
Sales in the first nine months of 2012 amounted to EUR 10,113 k, almost exactly the same as in the prior-year period (EUR 10,101 k), with the decline in license business sales (-6 %) being compensated by the rise in maintenance business sales (+10 %). The stable maintenance business amounted to 44 % of total sales in the first three quarters of this year, up from 41 % in 2011.
Sales in the Digital Mammography segment went down slightly by 1 % to EUR 7,694 k (prev. year: EUR 7,776 k). However, sales in the Other Diagnostics segment developed positively, rising by 4 % to EUR 2,419 k (prev. year: EUR 2,325 k).
Sales in the third quarter of 2012 came to EUR 3,235 k, on par with the second quarter but down 5 % on the third quarter of 2011.
Again, operating costs could be reduced in the third quarter. Personnel expenses after nine months amounted to EUR 6,253 k (prev. year: EUR 6,974 k) and other operating expenses to EUR 1,593 k, down EUR 1.1 million year on year (prev. year: EUR 1,983 k).
After depreciation and amortization in the amount of EUR 2,363 k (11 % down year-on-year) the earnings before interest and taxes (EBIT) rose by around EUR 1.3 million to EUR 1,951 k (prev. year: EUR 664 k), mainly due to cost cutting measures. The EBITDA margin significantly increased accordingly to 19 % (prev. year: 7 %).
The net financial result of EUR 65 k also increased significantly from EUR -438 k in the prior-year period, the contributing factors being the positive developments at the Dutch investment Medis and the strong US dollar.
Pre-tax earnings rose correspondingly by approximately EUR 1.8 million to EUR 2,016 k in the period under review (prev. year: EUR 226 k). Taking into account higher income tax expenses of EUR 1,544 k, which primarily continue to originate from non-cash deferred taxes, as well as a provision for possible tax arrears payments from previous years, MeVis closed the first three quarters of the current fiscal year with consolidated net profit of EUR 472 k (prev. year: EUR -923 k). Earnings per share amounted to EUR 0.27 (prev. year: EUR -0.54).
Cash and cash equivalents increased further in the third quarter of 2012 and amounted to EUR 9,734 k on September 30, 2012 (compared to EUR 7,506 k on December 31, 2011).
'We confirm our forecast for 2012, which states that we expect Group sales to stabilize at the same level as in the prior year, on account of business development in the first three quarters of 2012. Thanks to the sustained improvement to our cost position, we expect to achieve significantly higher EBIT than in 2011,' said Dr. Robert Hannemann, CFO of MeVis Medical Solutions AG. 'We also continue to anticipate renewed positive liquidity from operating activities this year, whereby a purchase price payment of up to EUR 3.0 million as part of the acquisition of the 49 % stake in MBS KG will be due for the last time at the end of this year, which will have a corresponding impact on liquidity.'
'We have continued with the implementation of our strategic realignment. We completed the closure of our Japanese subsidiary in October and will close our American subsidiary by the end of the year,' added Marcus Kirchhoff, CEO of MeVis Medical Solutions AG. 'We have now focused all our resources in Bremen, where we are continuing with our internal reorganization. Overall responsibility means that software development in the various segments has been harmonized and made more efficient. We have also appointed dedicated Key Account Managers to expand our industrial customer business.'
The financial reports of the company can be downloaded at http://www.mevis.de/mms/Finanzberichte.html .
End of Corporate News
12.11.2012 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
| Language: | English |
| Company: | MeVis Medical Solutions AG |
| Universitätsallee 29 | |
| 28359 Bremen | |
| Germany | |
| Phone: | +49 421 224 95 0 |
| Fax: | +49 421 224 95 11 |
| E-mail: | [email protected] |
| Internet: | http://www.mevis.de |
| ISIN: | DE000A0LBFE4 |
| WKN: | A0LBFE |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart |
| End of News | DGAP News-Service |
| - - - |
| 192545 12.11.2012 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.